Skip to contentI
Indaptus Therapeutics, Inc.
I
INDPIndaptus Therapeutics, Inc. INDP Q4 2021 · Indaptus Therapeutics, Inc. · ThalerReleased Mar 21, 2022, before the open
10-K filed Mar 21, 2022, 80 days after period end · 0001493152-22-007319
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$3.22M-$3.22MderivedN/M vs Q4 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Indaptus Therapeutics, Inc. · CIK 1857044 · Engraved from SEC EDGAR
N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$3,218,497— Operating Cash Flowderived-$3,539,715N/M Free Cash Flowderived-$3,539,715— ended Dec 31, 2021 · filed Mar 21, 2022 · 80 d after period end
0.8% from the close of Mar 18, 2022 to the close of Mar 21, 2022, the first after the release.
before the open$3.88$3.85 Feb 9Mar 21Apr 27